---
document_datetime: 2025-07-10 12:32:54
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/temozolomide-sun-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: temozolomide-sun-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 17.129395
conversion_datetime: 2025-12-17 09:31:49.202245
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## Temozolomide SUN

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency' s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessmenthistory'section.Forthecompleteproductlifecycleprocedures,youmayneedtoalsorefertoEPAR-Proceduralstepstakenandscientific informationafterauthorisation(archive).

| Applicationnumber   | Scope                                  | Opinion/ Notification 1 issued on   | Commission Decision IssuedÂ² / amendedon   | Product Information affected3   | Summary   |
|---------------------|----------------------------------------|-------------------------------------|-------------------------------------------|---------------------------------|-----------|
| Article 61(3) /     | -Notificationacc.Article61(3)-Accepted | 10/07/2025                          |                                           | Labelling                       |           |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions areissuedforallotherprocedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex Il, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (Eu) No. 712/2012, or within one year for other procedures.

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/N/0000271887                    | To implement the grey-shading of specific information inAnnexIIIAtoincorporate EDQMpatient-friendly terms androuteof administration abbreviations, thereby facilitating the production of multilingual packaging.                                                                                                                                                                                                                                                                                                                                                   |            |     |    |
|-------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----|
| Variation typeIB/ EMA/VR/0000235484 | Thiswas an applicationfor a group of variations. B.I.a.2 Changes in the manufacturing process of the active substance - B.I.a.2.e Minorchangeto therestrictedpartof an ActiveSubstanceMasterFile-Accepted B.I.d.1.a Re-test period/storage period - B.I.d.1.a.4Extension orintroduction of a re- test period/storage period supported by real time data - Accepted B.I.a.3 Change inbatchsize(includingbatch sizeranges)of active substance or intermediate used in the manufacturing process of the active substance - B.I.a.3.b Downscalingdownto10-fold-Accepted | 12/12/2024 | N/A |    |
| Article 61(3) / EMA/N/0000170864    | - Notification acc. Article 61(3) - Accepted Update of the package leaflet with revised contactdetailsoflocalrepresentatives.                                                                                                                                                                                                                                                                                                                                                                                                                                       | 12/04/2024 |     | PL |

<div style=\"page-break-after: always\"></div>